A patient who had previously undergone gastric bypass surgery developed severe malnutrition, micronutrient deficiencies, and acute liver injury after starting semaglutide, requiring ICU care and surgical reversal of the bypass.
ICU admission + bypass reversal requiredThe severity of this patient's malnutrition and liver injury was so extreme that it required intensive care, intravenous nutrition, and an endoscopic procedure to reverse the gastric bypass — illustrating how quickly the combination of bariatric surgery and GLP-1 therapy can become life-threatening.
What the researchers found
A post-Roux-en-Y gastric bypass patient developed profound micronutrient deficiencies and acute liver injury after initiating semaglutide therapy, requiring ICU admission, parenteral (IV) nutrition, and endoscopic bypass reversal. The case illustrates a 'dual-hit' mechanism where GLP-1 receptor agonists compound the nutrient absorption limitations already present after bariatric surgery, creating a potentially life-threatening nutritional crisis.
Why it matters
With millions of people having undergone bariatric surgery and the explosive growth of GLP-1 receptor agonists like semaglutide for weight management and diabetes, the overlap between these two patient populations is rapidly growing. This case serves as a critical safety warning that combining these interventions can be dangerous, and highlights the need for careful nutritional monitoring and risk assessment before prescribing GLP-1 drugs to post-bariatric patients.
How the study worked
This is a single-patient case report documenting the clinical course, diagnostic findings, and treatment of a post-bariatric surgery patient who developed severe complications after starting semaglutide. The report describes the patient's hospitalization, laboratory findings, and the interventions required.
What this study cannot tell us
As a single case report, this represents the experience of one patient and cannot establish how common this complication is. Individual factors such as dietary compliance, pre-existing nutritional status, and the specific details of the original surgery may have contributed to the severity. Case reports cannot demonstrate causation, only raise safety signals that warrant further investigation.
How to read the evidence
This is a single case report, the lowest level of clinical evidence. While it provides a valuable safety signal and clinical warning, it cannot establish incidence rates or prove a causal relationship between semaglutide and the complications in the context of prior bariatric surgery.
When this study was published
Published in 2026, this is a very recent case report reflecting the current clinical landscape where GLP-1 receptor agonists are being prescribed to an increasingly broad patient population, including those with prior bariatric surgery.
The bigger picture
As GLP-1 receptor agonists become among the most prescribed medications globally, clinicians are encountering novel safety concerns in specific patient populations. Post-bariatric surgery patients represent a growing and particularly vulnerable group. This case adds to emerging reports suggesting that the appetite-suppressing effects of GLP-1 drugs, combined with the malabsorptive anatomy of gastric bypass, can create a dangerous synergy that standard monitoring may not catch until it becomes critical.
Questions still open
- How common are serious nutritional complications when GLP-1 receptor agonists are prescribed to post-bariatric surgery patients?
- Should there be specific screening protocols or contraindication guidelines for GLP-1 drugs in patients with altered gastrointestinal anatomy?
- Could lower doses of GLP-1 receptor agonists be used safely in post-bariatric patients with appropriate nutritional monitoring?
Common questions
Why is combining semaglutide with gastric bypass potentially dangerous?
Should people with gastric bypass avoid GLP-1 drugs entirely?
Read the original research
Nutritional Vulnerability in RYGB Unmasked by GLP-1 Therapy.
ACG case reports journal, 13(3), e02032
Citation
Madej, Juliana; Gonzaga, Ernesto Robalino; Naveed, Mariam. (2026). Nutritional Vulnerability in RYGB Unmasked by GLP-1 Therapy.. ACG case reports journal, 13(3), e02032. https://doi.org/10.14309/crj.0000000000002032